---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-028420"
form_type: "8-K/A"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2025-02-18T23:59:59+00:00"
generated_at: "2026-05-26T17:07:11.806972+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cabaletta reports deepened rese-cel responses: 3 SLE patients in DORIS remission, LN complete renal response

## Summary
- 3 of 4 non-renal SLE patients achieved DORIS remission; first LN patient achieved complete renal response; all off immunosuppressants and steroids.
- First adult dermatomyositis patient maintained major TIS improvement at 3 months, off immunosuppressants and tapering steroids.
- Safety: 90% had no CRS or Grade 1 CRS; 90% had no ICANS across first 10 patients dosed with rese-cel.
- Deep B cell depletion within first month; repopulation with naïve phenotype starting ~2 months post-infusion; tissue depletion confirmed by lymph node biopsy.
- 50 clinical sites recruiting in US/Europe; 26 patients enrolled across RESET program as of Feb 13, 2025; average 1 patient/week since November.

## SEC filing metadata
- accession: 0001193125-25-028420
- form_type: 8-K/A
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2025-02-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000119312525028420/0001193125-25-028420-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000119312525028420/d925657d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-028420
- JSON: https://secwatch.observer/filing/0001193125-25-028420.json
- Plain text: https://secwatch.observer/filing/0001193125-25-028420.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.